CanAg® CA15-3 EIA

The MUC 1 antigen is a membrane-anchored, mucin-type glycoprotein present in malignant and normal epithelial cells of certain organs (ie, breast, lung, ovary, pancreas, and colon)1. The apoprotein of the MUC 1 mucin contains a transmembrane domain, a cytoplasmic domain, and an extracellular carbohydrate-rich domain. The extracellular domain is characterized by polymorphism with respect to the number of a 20 amino acid tandem repeat (VNTR polymorphism). The CA15-3 EIA is based on two mouse monoclonal antibodies, Ma695 as catcher antibody recognizing a sialylated carbohydrate epitope expressed on the MUC 1 antigen and Ma552 as tracer antibody targeting the PDTRPAPG region of the protein core2-5.The MUC 1 breast cancer mucin (CA15-3 antigen) is secreted from tumor cells and is a well-established serological marker for monitoring the clinical course of breast cancer patients6.


  1. Bon, G., Kenemans, P., Yedema, C.A., vanKamp, G.J., Nijman, H.W., and Hilgers, J. (1990) Clinical relevance of the tumor marker CA15.3 in the management of cancer patients in “From Clone to Clinic” p. 111-122, Crommelin and Schellekens (eds.) Kluwer Academic Publishers.

  2. Nilsson O., Karlsson B., Lindholm L., Pettersson A. (1994) Development of assays for determination of MUC 1 breast cancer antigen, 7th Symposium on Tumor Markers, Hamburg 1993, R Klapdor (ed) Current Tumor Diagnostics: Applications, Clinical Relevance, Research, Trends. W. Zuckswerdt Verlag München, 1994.

  3. Bäckström D., Nilsson O., Price MR., Lindholm L., Hansson GC. Discrimination of MUC1 mucins from other Sialyl-Lea-carrying glycoproteins by colon carcinoma cells using a novel monoclonal antibody. Cancer Res., 53, 755, 1993.

  4. Blockzjil A, Nilsson K, and Nilsson O. (1998) Epitope characterization of MUC1 antibodies. Tumor Biology 19 suppl. 1:46-56.

  5. Price M.R. et al., (1998) Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin Tumor. Biology 19 suppl. 1:1-20.

  6. Fleisher M. et al. (2002) Practice guidelines and recommendations for use of tumor markers in the clinic. National Academy of Clinical Biochemistry 15: 26-29.

Contact sales for information
CE marked
CanAg CA15-3 EIA

Product number 200-10

For 96 determinations
Please contact your local Fujirebio representative for the availability of this product in your country.
  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: